Publikation: Luteinizing hormone-releasing hormone antagonists
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
DOI (zitierfähiger Link)
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.
Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented.
Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
MEZÖ, Gábor, Marilena MANEA, 2009. Luteinizing hormone-releasing hormone antagonists. In: Expert Opinion On Therapeutics Patents. 2009, 19(12), pp. 1771-1785. ISSN 1354-3776. eISSN 1744-7674. Available under: doi: 10.1517/13543770903410237BibTex
@article{Mezo2009Lutei-9668,
year={2009},
doi={10.1517/13543770903410237},
title={Luteinizing hormone-releasing hormone antagonists},
number={12},
volume={19},
issn={1354-3776},
journal={Expert Opinion On Therapeutics Patents},
pages={1771--1785},
author={Mezö, Gábor and Manea, Marilena}
}RDF
<rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/9668">
<dc:contributor>Manea, Marilena</dc:contributor>
<dcterms:title>Luteinizing hormone-releasing hormone antagonists</dcterms:title>
<dc:language>eng</dc:language>
<dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/9668/1/Mezo_EOTP_2009.pdf"/>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T18:13:34Z</dc:date>
<dc:format>application/pdf</dc:format>
<dcterms:issued>2009</dcterms:issued>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52"/>
<dc:creator>Mezö, Gábor</dc:creator>
<dc:creator>Manea, Marilena</dc:creator>
<bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/9668"/>
<dc:rights>terms-of-use</dc:rights>
<dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/9668/1/Mezo_EOTP_2009.pdf"/>
<dcterms:bibliographicCitation>First publ. in: Expert Opinion On Therapeutics Patents ; 19 (2009), 12. - S. 1771-1785</dcterms:bibliographicCitation>
<dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
<dcterms:abstract xml:lang="eng">Luteinizing hormone-releasing hormone (LH-RH) plays a central role in the vertebrate reproduction by regulating gonadal activity. Based on its binding to pituitary LH-RH receptors, as well as to LH-RH receptors expressed on cancer cells, LH-RH agonists and antagonists have been developed for different therapeutic applications.<br />Objective/method: Here we give an overview of the most relevant LH-RH antagonists and their therapeutic applications. Recently patented compounds as well as drug formulations and dosage are presented.<br />Conclusion: LH-RH antagonists have found clinical applications in in vitro fertilization, benign prostatic hyperplasia, endometriosis and in the treatment of hormone-dependent tumors. Work in progress is focused on further development of both peptidic and orally active non-peptidic LH-RH antagonists.</dcterms:abstract>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52"/>
<dc:contributor>Mezö, Gábor</dc:contributor>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
</rdf:Description>
</rdf:RDF>